• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Chee Choon Wee claimed ownership of 6,830,402 shares (SEC Form 3)

    9/25/25 5:00:15 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HSDT alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Chee Choon Wee

    (Last) (First) (Middle)
    C/O HELIUS MEDICAL TECHNOLOGIES, INC.
    642 NEWTOWN YARDLEY RD #100

    (Street)
    NEWTOWN PA 18940

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    09/18/2025
    3. Issuer Name and Ticker or Trading Symbol
    HELIUS MEDICAL TECHNOLOGIES, INC. [ HSDT ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    COMMON STOCK 6,830,402 I By Fusion Summer Limited(1)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    STAPLED WARRANT (2) (2) Common Stock 6,830,402 $10.134 I By Fusion Summer Limited(1)
    RESTRICTED STOCK UNIT AWARD (3) (3) Common Stock 1,109,118 (4) D
    Explanation of Responses:
    1. Summer Wisdom Holdings Limited ("Summer Wisdom") holds all ordinary shares of Fusion Summer Limited ("Fusion Summer"). Fusion Summer holds shares of the Issuer's common stock. The Reporting Person is the Controlling Shareholder of Summer Wisdom. Summer Wisdom may be deemed to be the beneficial owner of all of the common stock held by Fusion Summer. The Reporting Person, as the Controlling Shareholder of Summer Wisdom with sole power to exercise investment discretion, may be deemed to be the beneficial owner of all of the common stock held by Fusion Summer. The Reporting Person is the Issuer's Executive Chairman of its Board of Directors.
    2. The Stapled Warrant may be exercised only during the period beginning September 18, 2025 (the "Issue Date") of the Warrant, and ending on 5:00 p.m., New York City time, on the date that is thirty-six (36) months after the Issue Date of the Warrant.
    3. The restricted stock units (RSUs) granted on September 18, 2025, are subject to the conditions set forth in the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan.
    4. Each restricted stock unit represents a contingent right to receive one share of Helius Medical Technologies, Inc. Common Stock.
    /s/ Joseph Chee 09/25/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HSDT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSDT

    DatePrice TargetRatingAnalyst
    11/15/2021Outperform → Market Perform
    Noble Capital Markets
    More analyst ratings

    $HSDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Helius Announces FDA 510(k) Submission for PoNS® Device Label Expansion in Stroke

    NEWTOWN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), today announced the filing of its U.S. Food and Drug Administration (FDA) 510(k) submission for the PoNS (Portable Neuromodulation Stimulator) device label expansion seeking an indication for gait and balance deficit in patients with chronic stroke symptoms. The submission was made with data generated in its Stroke Registrational Program (SRP) and was filed under its current FDA Breakthrough Device Designation. All statistical analyses for the Functional Gait Assessment (FGA) primary endpoint demonstrated PoNS superior effectiveness in improving gait deficit by achieving a clinically meani

    9/25/25 7:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius (NASDAQ:HSDT) Begins Purchases of SOL, the Native Asset of Solana Blockchain

    NEWTOWN, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (the "Company" or "HSDT"), today announced its first acquisition of Solana ("SOL") tokens as part of its digital asset treasury strategy under which the principal holding will be SOL, the native digital asset of the Solana Blockchain. The Company now holds over 760,190 SOL, with an average cost basis of $231. The Company also holds in excess of $335 million of cash, which it intends to use to further the digital asset treasury strategy. These SOL purchases underscore HSDT's commitment to the Company's Solana treasury strategy and long-term confidence in the Solana ecosystem. "We are excited to embark on ou

    9/22/25 7:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius (NASDAQ:HSDT), in Partnership with Pantera Capital and Summer Capital Closes Over $500 Million Private Placement to Launch SOL Treasury Company

    Preeminent SOL-backed treasury vehicle - with potential to raise over $1.25 billion aggregate gross proceeds - unlocks capital markets to accelerate Solana's growth The financing drew participation from leading investors across traditional finance and crypto, including Big Brain Holdings, Avenir, SinoHope, FalconX, Arrington Capital, Animoca Brands, Aspen Digital, Borderless, Laser Digital, HashKey Capital, and Republic Digital NEWTOWN, Pa., Sept. 18, 2025 /PRNewswire/ -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company") today announced that it has closed its previously announced private placement offering (the "Offering") of common stock and stapled warrants to pur

    9/18/25 3:33:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Andreeff Dane bought $8,229 worth of shares (1,284 units at $6.41) (SEC Form 4) (Amendment)

    4/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    2/15/24 4:06:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Andreeff Dane bought $40,475 worth of shares (5,000 units at $8.10) (SEC Form 4)

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    12/15/23 7:00:42 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Andreeff Dane bought $25,675 worth of shares (4,006 units at $6.41) (SEC Form 4)

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    12/4/23 8:30:12 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Helius Medical Tech downgraded by Noble Capital Markets

    Noble Capital Markets downgraded Helius Medical Tech from Outperform to Market Perform

    11/15/21 10:55:44 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Noble Capital Markets initiated coverage on Helius Medical with a new price target

    Noble Capital Markets initiated coverage of Helius Medical with a rating of Outperform and set a new price target of $20.00

    3/24/21 8:02:45 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LADENBURG THALM/SH SH initiated coverage on Helius Medical Technologies

    LADENBURG THALM/SH SH initiated coverage of Helius Medical Technologies with a rating of Buy

    2/12/21 8:21:57 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Chee Choon Wee claimed ownership of 6,830,402 shares (SEC Form 3)

    3 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    9/25/25 5:00:15 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by CFO and Treasurer Mathiesen Jeffrey S

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    7/3/25 8:00:26 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Chief Medical Officer Favit-Van Pelt Antonella R.

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    7/3/25 8:00:28 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    SEC Filings

    View All

    Helius Medical Technologies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

    9/25/25 9:00:18 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

    9/22/25 7:22:42 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form S-3ASR filed by Helius Medical Technologies Inc.

    S-3ASR - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

    9/19/25 8:22:53 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Financials

    Live finance-specific insights

    View All

    Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device

    NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today provided updates on its efforts to achieve fair market access for its Portable Neuromodulation Stimulator (PoNS) device and announced plans to host a business update call today at 9:00am ET.   "We disagree with the proposed pricing for the PoNS Mouthpiece and are disappointed CMS has once again mapped the Controller pricing to a code for fundamentally different technology," said Dane Andreeff, Helius' President and Chief Executive Officer. "I

    11/18/24 8:01:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024

    NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its second quarter 2024 financial results on Monday, August 12, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date:Monday, Augus

    8/6/24 4:36:06 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024

    NEWTOWN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its first quarter 2024 financial results on Monday, May 13, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date: Monday, May 13, 2

    5/10/24 9:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Leadership Updates

    Live Leadership Updates

    View All

    Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device

    -Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS- NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare. "The recent reimbursement approvals from two major

    6/11/25 7:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting

    NEWTOWN, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced it will highlight the results of a new study confirming the therapeutic regimen and sustained efficacy of its Portable Neuromodulation Stimulator (PoNS®) device for people with multiple sclerosis (MS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. The event runs from May 28-31 at the Phoenix Convention Center in Phoenix. Deborah Backus, PT, Ph.D., FACRM – Vice President of Research and Innovation at Atlanta's Shepherd Center, one of six sit

    5/20/25 7:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Technologies, Inc. Appoints Paul Buckman to its Board of Directors

    NEWTOWN, Pa., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced the appointment of Paul Buckman to its Board of Directors, effective September 10, 2021. Mr. Buckman will serve as Chair of the Company's Audit Committee and as a member of its Compensation and Nominating & Governance Committees. "Paul is a highly accomplished executive with more than 30 years of experience in the medical device sector, including senior leadership positions at some of the most well-regarded companies in the industry," said Blane Walter, Chairman of Helius' Board of Directors. "I

    9/14/21 7:05:00 AM ET
    $HSDT
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Helius Medical Technologies Inc.

    SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    11/8/24 5:12:24 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Helius Medical Technologies Inc.

    SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    5/14/24 4:15:39 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Helius Medical Technologies Inc. (Amendment)

    SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    2/13/24 7:09:07 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care